Labcorp to Acquire BioReference Health Assets from OPKO for $722M
Event summary
- Labcorp will acquire select assets of BioReference Health from OPKO Health for $722M in cash, with up to an additional $150M in earnout based on 4Kscore Test revenue.
- The deal includes over 80 patient service centers and BioReference's proprietary 4Kscore Test for prostate cancer risk assessment.
- Labcorp expects the acquired business to generate approximately $250M in revenue in the first year post-closing.
- The transaction is subject to regulatory approvals and customary closing conditions.
- OPKO aims to streamline operations and focus on its biopharmaceutical business following the sale.
The big picture
This acquisition strengthens Labcorp's position in the clinical and women's health testing markets, expanding its specialty testing menu and patient service center network. The deal aligns with Labcorp's strategy to enhance its diagnostic capabilities and broaden access to innovative testing services. For OPKO, the transaction allows the company to focus on its biopharmaceutical business while monetizing its diagnostics assets.
What we're watching
- Integration Challenges
- How Labcorp will integrate BioReference's operations and patient service centers into its existing network.
- Regulatory Approvals
- The pace at which regulatory approvals will be secured and the potential impact on the transaction timeline.
- Earnout Performance
- Whether the additional $150M earnout based on 4Kscore Test revenue will be realized, given Labcorp's post-closing forecasts.
Related topics
